184 - New Perspectives on an Ancient Disease: Hepatitis B Management

Friday, October 21, 2022

3:15 PM – 4:30 PM US ET

Location: 150 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Michael Melia, MD

ID Fellowship Program Director
Johns Hopkins University
Baltimore, Maryland, United States

Disclosure(s): No financial relationships to disclose
Susanna Naggie, MD/MHS

Professor of Medicine with Tenure/Vice Dean of Clinical Research
DCRI/ School of Medicine
Durham, North Carolina, United States

Disclosure(s): AbbVie: Grant/Research Support (); BMS/PRA: Event adjudication (); Gilead Sciences: Grant/Research Support (); Pardes Biosciences: Advisor/Consultant (); Personal Health Insights, Inc: Data Safety Monitoring Board Member (); Silverback Therapeutics: Advisor/Consultant (); Vir Biotechnology: Advisor/Consultant (), Stocks/Bonds ()

Faculty(s)

Ashwin Balagopal, MD

Associate Professor of Medicine
Johns Hopkins School of Medicine

Disclosure(s): No financial relationships to disclose

Slides
Debika Bhattacharya, MD, MSc

Associate Clinical Professor
Medicine
University of California, Los Angeles, Greater Los Angeles Veteran Affairs
Los Angeles, CA, United States

Disclosure(s): Gilead Biosciences: Grant/Research Support (Ongoing)

Slides
David Thomas, MD

Professor of Medicine
Johns Hopkins
Baltimore, MD, United States

Disclosure(s): Excision Biotherapeutics: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Expert Testimony (Ongoing)

Slides

Disclosure(s):

Michael T. Melia, MD: No financial relationships to disclose

Susanna Naggie, MD/MHS: AbbVie: Grant/Research Support (); BMS/PRA: Event adjudication (); Gilead Sciences: Grant/Research Support (); Pardes Biosciences: Advisor/Consultant (); Personal Health Insights, Inc: Data Safety Monitoring Board Member (); Silverback Therapeutics: Advisor/Consultant (); Vir Biotechnology: Advisor/Consultant (), Stocks/Bonds ()

Ashwin Balagopal, MD: No financial relationships to disclose

Debika Bhattacharya, MD, MSc: Gilead Biosciences: Grant/Research Support (Ongoing)

David Thomas, MD: Excision Biotherapeutics: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Expert Testimony (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the argument for individualized decision-making in HBsAg-positive patients;
discuss arguments in support of treating patients with persistent HBV viremia;
describe the clinical data regarding the use of long-acting HBV therapeutics

Presentations:

3:15 PM – 3:40 PM US ET

Are All HBsAg-Positive Patients Alike? The Argument for Individualized Decision-Making
Speaker: Ashwin Balagopal, MD – Johns Hopkins School of Medicine
3:40 PM – 4:05 PM US ET

Universal HBV Treatment? The Argument for Treating All Persons Living With HBV
Speaker: Debika Bhattacharya, MD, MSc – University of California, Los Angeles, Greater Los Angeles Veteran Affairs
4:05 PM – 4:30 PM US ET

Long-Acting HBV Treatment: Dream or Reality?
Speaker: David Thomas, MD – Johns Hopkins